At the Consumer Electronics Show in Las Vegas this week, Withings unveiled its latest innovation in home health monitoring: the Body Scan 2 smart scale, priced at $599.95. The device, which the company describes as a 'longevity station,' promises to track over 60 biomarkers related to cardiovascular and metabolic health, offering users a comprehensive snapshot of their wellness with each weigh-in. Announced on Tuesday amid a flurry of gadget reveals at CES 2026, the scale builds on Withings' previous models by incorporating advanced noninvasive measurements that could signal early health risks without the need for blood tests or doctor visits.
The Body Scan 2 features eight electrodes embedded in the scale's platform and four more in a retractable handle, allowing it to capture data from both the lower and upper body for greater accuracy. Unlike standard smart scales that rely solely on foot sensors to estimate body composition, this design integrates upper-body metrics, providing a more holistic view. According to Withings, the scale will measure essentials like weight and heart rate, but its standout addition is a 90-second 'longevity assessment' that evaluates metrics across five key categories: heart pumping performance and electrical activity, hypertension risk, artery health, cellular health and metabolic efficiency, and glycemic regulation.
'We have been building this vision of adding a lot of powerful biomarkers that can be measured every day when you step on the scale,' said Antoine Joussain, Withings' director of product management for devices, in an interview at the show. This daily tracking aims to empower users with actionable insights into their healthspan—the number of years they can expect to live in good health. To avoid overwhelming users with data, the scale generates a simplified Health Trajectory score, visualized in the accompanying Withings app, which condenses the 60-plus metrics into easy-to-follow indicators.
'We want to keep it simple on a high level, so you have clear indicators that you can follow on a daily, weekly, or monthly basis. The rest of the 60 biomarkers, you can of course review them, but we’ll do all the interpretation for you,' Joussain explained. This approach echoes recent trends in wearable health tech, where companies are shifting from raw data dumps to interpretive scores that mimic professional medical assessments.
Withings isn't alone in this space. In 2025, Whoop rolled out a similar aging metric with its Whoop 5.0 fitness tracker, combining cardiovascular, sleep, and activity data to estimate biological age. Similarly, Oura introduced cardiovascular age comparisons to chronological age in its rings back in 2024, and both firms added optional blood test integrations for deeper metabolic insights last year. What sets the Body Scan 2 apart, however, is its emphasis on noninvasive metabolic tracking, achieved through bioimpedance spectroscopy (BIS) and analysis of foot sweat.
The scale uses BIS by sending low-frequency electrical currents through the body to assess cell membrane function, a key indicator of metabolic health. For sweat analysis, it applies a safe, tiny current to stimulate the foot's sweat glands and measures their response. 'The goal is to stimulate the sweat glands that are inside your feet with a safe, tiny current. We measure the maximum activity response from these sweat glands. If the activity is high, to simplify a bit, it means your glands are healthy and if not, they’re not healthy,' Joussain said. He noted that conditions like diabetes often impair foot sweat production, and Withings has observed correlations in data from users with uncontrolled diabetes.
These features are positioned as early warning tools rather than diagnostic ones, encouraging users to consult physicians for confirmation. Joussain highlighted the convenience of a scale as the central hub for such monitoring, given that many households already incorporate daily weigh-ins into routines. Yet, he acknowledged potential pitfalls, particularly the emotional weight—pun intended—that scales carry for some individuals prone to body image issues or eating disorders.
To address this, Withings has included an Eyes-Closed Mode, where the scale displays only emojis instead of numerical readouts, while still logging data in the app for later review. 'Long-term, he says the hope is to reenvision the scale as a “longevity station” that measures overall health—not just weight,' according to reports from the event. This reframing aligns with broader industry efforts to destigmatize weight-focused devices and promote them as multifaceted health tools.
Regulatory hurdles remain a significant challenge for Withings, as with many health tech firms. Two key features of the Body Scan 2—the hypertension risk notifications and a six-lead electrocardiogram (EKG) for detecting atrial fibrillation—will require clearance from the U.S. Food and Drug Administration. Withings has a mixed track record here: Its ScanWatch smartwatch took nearly two years to gain FDA approval, while the Move ECG, announced in 2019, still hasn't launched in the U.S. market. The company previously sidestepped clearance for its U-Scan urinalysis device by marketing it as a wellness product rather than a medical one.
Joussain expressed optimism about streamlining the process. He mentioned that Withings is pursuing a 'new kind of certification' designed to expedite approvals without compromising scientific rigor, potentially getting devices to market faster. The scale will also comply with GDPR and HIPAA privacy standards, along with ISO 27001 and ISO 27701 certifications for data security. If timelines hold, the Body Scan 2 is slated for release in the second quarter of 2026.
CES 2026, held at the Las Vegas Convention Center from January 7 to 10, has been a hotspot for health and wellness announcements, reflecting a post-pandemic surge in consumer interest in at-home diagnostics. Withings' reveal comes at a time when the global smart scale market is projected to grow significantly, driven by integrations with apps and AI-driven insights. Analysts point to rising chronic disease rates—heart disease and diabetes affect millions worldwide—as fueling demand for accessible monitoring tools.
Critics, however, caution that while noninvasive tech like BIS shows promise, its accuracy compared to lab tests needs validation through large-scale studies. Some experts worry that over-reliance on consumer devices could lead to unnecessary anxiety or delayed professional care. Withings maintains that its biomarkers are backed by ongoing research, with the company collaborating with medical professionals to refine algorithms.
Beyond individual users, the Body Scan 2 could influence how insurers and healthcare providers view home health data. If cleared, features like EKG and hypertension alerts might integrate with telehealth platforms, enabling proactive interventions. Joussain emphasized the scale's role in democratizing health metrics, making advanced assessments available beyond clinical settings.
As CES wraps up, Withings' push into longevity tech underscores a larger shift in consumer electronics toward preventive health. With competitors like Whoop and Oura expanding their ecosystems, the race is on to make sophisticated monitoring seamless and affordable—though at nearly $600, the Body Scan 2 targets a premium audience. For those eyeing an upgrade, the wait until mid-2026 might be worth it, pending regulatory green lights.
In the meantime, Withings continues to iterate on its lineup, drawing from user feedback to balance innovation with usability. The company's presence at CES highlights Las Vegas as the epicenter of tech trends, where a simple scale can evolve into a cornerstone of personal health management.